Peer-Reviewed Publications

      Phenolic compound formation from the low temperature pyrolysis of tobacco

      McGrath, T. E.; Brown, A. P.; Meruva, N. K.; Chan, W. G.
      Published
      Feb 4, 2009
      DOI
      10.1016/j.jaap.2009.01.008
      Link to publication
      Topic
      Summary

      The formation of 10 phenolic compounds (hydroquinone, resorcinol, catechol, phenol, 4-methylcatechol, 3-methylcatechol, guaiacol, o-, m-, and p-cresol) from the pyrolysis of different tobacco types at temperatures between 350 and 600 °C was investigated. Hydroquinone, catechol, guaiacol, 3-methylcatechol, and 4-methylcatechol were formed predominately at temperatures ≤350 °C from the primary decomposition of tobacco components. Cresols formed predominately between 350 and 600 °C and evolved from the residual solid (char) that forms at temperatures above 350 °C. Phenol and resorcinol were found to form over both temperature ranges, ≤350 °C and between 350 and 600 °C suggesting contributions from both the decomposition of tobacco components and the 350 °C residual solid. The trend in the yields of hydroquinone and catechol obtained from the tobacco types tested; bright (flue cured), burley, and oriental followed bright ∼ oriental > burley. All three tobacco samples gave similar yields of phenol and cresols. Water extraction of tobacco was shown to significantly reduce the yields of phenolic compounds. The addition of 5 and 21% oxygen to the pyrolysis setup led to a significant reduction in the yields of hydroquinone and catechol but the yields of phenol and cresols remained relatively unchanged. Quinic acid and quinic acid derivatives present in tobacco are identified as important precursors of hydroquinone, catechol, and phenol.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.